Safety Study of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Recruitment status was: Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Acute lung injury (ALI) is caused by a wide variety of conditions, but always characterized by hypoxia and non-cardiogenic pulmonary edema. Current treatment of ALI is supportive and treatment of the underlying cause. New therapies to treat severe ALI have not been shown to improve survival, and are limited by financial and logistical resources.
The investigators propose to investigate the role of inhaled sodium nitroprusside (iSNP) in ALI. Sodium nitroprusside (SNP) is a vasodilator. When inhaled, SNP may travel to areas of the lung participating in gas exchange, and cause the blood vessels surrounding these areas to enlarge. This may result in an increase of blood vessels to these areas of the lung, and improve oxygenation. Currently, iSNP has not been studied in the adult population. Therefore, this study is intended to find the safety profile of varying doses of iSNP.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Lung Injury Acute Respiratory Distress Syndrome Sodium Nitroprusside Hypoxia Respiratory Failure |
Drug: Sodium Nitroprusside |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury |
- The maximum tolerable dosage of nebulized sodium nitroprusside. This will be determined by the 3 + 3 dose finding design. [ Time Frame: Up to 1 year ]Participants will be followed for the duration of the intervention of 45 min. . It is anticipated it will take up to 1 year to recruit the required number of participants to determine the maximum tolerable dose of nebulized sodium nitroprusside.
- The change in measures of oxygenation (PaO2,SaO2,oxygenation index) during iSNP administration. [ Time Frame: 0 min, 15 min, 30 min, and 45 min ]
- The change in heart rate (HR), mean blood pressure (MAP) during iSNP administration. [ Time Frame: 0 min, 15 min, 30 min, and 45 min ]
- The presence or absence of lactate, and/or methemoglobin. [ Time Frame: 0 min, 15 min, 30 min, and 45 min ]
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2012 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Nebulized sodium nitroprusside |
Drug: Sodium Nitroprusside
Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
Other Name: Nipride, Nitropress
|
Detailed Description:
Acute lung injury (ALI) is a syndrome characterized by acute hypoxemic respiratory failure with bilateral pulmonary infiltrates that are not attributed to left atrial hypertension. ALI is responsible for significant mortality and morbidity in the critically ill population.
Novel rescue therapies used to support oxygenation in severe ALI include inhaled nitric oxide and high frequency oscillatory ventilation; however, neither have been shown to reduce mortality and both are limited by logistical and financial challenges.
Inhaled sodium nitroprusside (iSNP) is a vasodilator which causes local vasodilation of pulmonary capillaries surrounding functional alveoli, resulting in improved oxygenation by redistributing pulmonary blood flow to areas with better ventilation-perfusion ratios. As iSNP can be administered by a low-cost nebulizer and is relatively inexpensive compared to other novel rescue therapies, this modality may be an alternative therapy for patients with severe hypoxemia. Two pediatric studies support the use of iSNP in ALI; however, iSNP has not been studied in the adult ALI population. To determine whether iSNP can improve oxygenation in adult ALI, the maximum tolerable dose (MTD) must first be determined.
Our study aims to determine the MTD of iSNP in adult ALI through an open-label, non-randomized, single centered, dose escalation study design, whereby subjects will receive iSNP for thirty minutes and have various physiologic variables recorded.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18
- Negative β-hCG in women of child bearing age (age ≤ 50)
-
Developed ALI within past 72 hours:
- PaO2/FiO2 < 300;
- Bilateral infiltrates on CXR;
- No clinical evidence of elevated left atrial pressure ie. Heart failure as the cause of hypoxia and bilateral infiltrates; and
- Recognized risk factor for ALI such as: pneumonia, aspiration pneumonitis, acute pancreatitis, massive blood transfusion, or sepsis
- FiO2 ≥ 0.5
- PEEP ≥ 8 cm H2O
- Invasive arterial blood pressure line
- Endotracheal intubation or tracheostomy
- Conventional mechanical ventilation
- Mean Arterial Pressure (MAP) ≥ 65 mmHg with or without use of vasopressors (stable for at least more than 1 hour)
- Arterial pH ≥ 7.15
Exclusion Criteria:
- Chest tube with active leak (eg. bronchopulmonary fistula),
- Prone ventilation, inhaled nitric oxide, inhaled prostacyclin, high frequency oscillatory ventilation,
- Lack of consent,
- Untreated coarctation of aorta, symptomatic or severe/critical aortic stenosis as documented by echocardiogram or clinical history,
- Evidence of increased intracranial pressure (eg. dilated pupils, known intracranial trauma or mass on head CT),
- SpO2 <90%,
- Contraindication to SNP i.e. hypersensitivity, congenital optic atrophy, tobacco amblyopia,
- Active treatment with IV or transdermal nitroglycerin,
- G6PD deficiency
- CrCl < 30 ml/min or receiving renal replacement therapy, or
- Total bilirubin > 68 µmol/L and AST or ALT level 2 times the upper limit of normal.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01619280
| Contact: Terence Ip, MD | terence.ip@utoronto.ca |
| Canada, Ontario | |
| Mount Sinai Hospital, University of Toronto | Recruiting |
| Toronto, Ontario, Canada, M5G 1X5 | |
| Principal Investigator: Terence Ip, MD | |
| Principal Investigator: Sangeeta Mehta, MD FRCPC | |
| Sub-Investigator: Lisa Burry, PharmD | |
| Sub-Investigator: Cynthia Harris, RRT | |
| Sub-Investigator: John Traill, RRT | |
| Sub-Investigator: Niall Ferguson, MD, FRCPC | |
| Principal Investigator: | Sangeeta Mehta, MD FRCPC | Department of Critical Care Medicine, University of Toronto |
| Principal Investigator: | Terence Ip, MD | Department of Critical Care Medicine, University of Toronto |
More Information
| Responsible Party: | Mount Sinai Hospital, Canada |
| ClinicalTrials.gov Identifier: | NCT01619280 History of Changes |
| Other Study ID Numbers: |
10-0102-A |
| Study First Received: | May 29, 2012 |
| Last Updated: | June 12, 2012 |
Keywords provided by Mount Sinai Hospital, Canada:
|
Acute Lung Injury Acute Respiratory Distress Syndrome Sodium Nitroprusside adult Safety Dose Finding Phase 1 |
3 + 3 design Nebulizers and Vaporizers High-Frequency Ventilation nitric oxide lung injury Pulmonary Gas Exchange Pulmonary Alveoli |
Additional relevant MeSH terms:
|
Wounds and Injuries Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiratory Insufficiency Acute Lung Injury Lung Injury Lung Diseases Respiratory Tract Diseases Respiration Disorders |
Infant, Premature, Diseases Infant, Newborn, Diseases Thoracic Injuries Nitroprusside Antihypertensive Agents Vasodilator Agents Nitric Oxide Donors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 25, 2017